(OZEM) Roundhill GLP-1 & Weight - Overview
Etf: Pharmaceutical, Biotech, Healthcare, Derivatives, Swap
Dividends
| Dividend Yield | 1.19% |
| Yield on Cost 5y | 1.64% |
| Yield CAGR 5y | 673.58% |
| Payout Consistency | 83.3% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 40.2% |
| Relative Tail Risk | -1.02% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.20 |
| Alpha | 28.51 |
| Character TTM | |
|---|---|
| Beta | 0.735 |
| Beta Downside | 0.686 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.65% |
| CAGR/Max DD | 0.76 |
Description: OZEM Roundhill GLP-1 & Weight January 06, 2026
The Roundhill GLP-1 & Weight-Loss ETF (NASDAQ: OZEM) is a non-diversified fund that must allocate at least 80 % of its net assets-plus any investment-purpose borrowings-to equity securities of companies developing GLP-1-based therapies or to derivatives (e.g., swaps, forwards) that reference those companies.
Key sector drivers include a projected 12-15 % CAGR for global GLP-1 sales through 2028, driven by rising obesity rates (≈42 % of U.S. adults) and expanding insurance coverage for injectable weight-loss drugs. Recent FDA approvals (e.g., Wegovy, Ozempic) have lifted the combined market capitalization of the top five GLP-1 firms to over $300 billion, while pipeline candidates in Phase III are expected to add another $10-15 billion in revenue potential if approved.
For a deeper dive into OZEM’s exposure metrics and risk profile, you might explore the fund’s analytics on ValueRay to see how its concentration compares to broader health-care benchmarks.
What is the price of OZEM shares?
Over the past week, the price has changed by -2.56%, over one month by +1.05%, over three months by +19.76% and over the past year by +39.42%.
Is OZEM a buy, sell or hold?
What are the forecasts/targets for the OZEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 41.1 | 17.4% |
OZEM Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 60.0m USD (60.0m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 60.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 60.0m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.62% (E(60.0m)/V(60.0m) * Re(8.62%) + (debt-free company))
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)